Understanding the use of PARPi combinations to treat patients with mCRPC
Scientific Director of the 'Istituto Clinico Humanitas' and Professor of General Pathology at the University of Milan, Italy, talks to ecancer at AACR 2009 about his work with chemokines- blocking chemokines to supress tumour growth, and increasing eligibility of patients to recieve bone marrow transplants.
Understanding the use of PARPi combinations to treat patients with mCRPC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Durable responses in aRCC, how do we optimise treatment?
Best practice in HRRm testing in patients with metastatic prostate cancer
Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC
EAU 2024: Bladder cancer latest
Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC